Integra LifeSciences Holdings Corporation

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Integra LifeSciences Holdings Corporation (NASDAQ: IART) between March 11, 2019 through May 22, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 13, 2023.

If you purchased Integra common stock and would like to join the action, please click “Join This Class Action.”

集体诉讼期:March 11, 2019 through May 22, 2023


48 Days
If you purchased Integra common stock during Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.


According to the lawsuit, throughout the Class Period defendants made false statements and/or concealed that Integra had failed to take sufficient measures to remediate the violations identified by the U.S. Food and Drug Administration (“FDA”) in the November 2, 2018 Notice of Inspectional Observations on Form 483, the March 6, 2019 FDA issued warning letter, and the November 12, 2021 FDA issued Form 483. As a result of those deficiencies, since March 2018, all products manufactured in the Company’s manufacturing plant located in Boston, Massachusetts (the “Boston Facility”), including SurgiMend, PriMatrix, Revize, and TissueMend, had the potential for higher-than-permitted levels of endotoxin and would need to be recalled. Moreover, Integra was not making progress towards obtaining its premarket approval (“PMA”) indication for SurgiMend, in part, because the manufacturing site that would produce the PMA product, the Boston Facility, was in continued violation of the FDA standards that Integra failed to rectify years after the initial notice of the violations and as a result the facility had to be shutdown to correct those ongoing deficiencies. When the true details entered the market, the lawsuit claims that investors suffered damages.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Attorney Advertising. Prior results do not guarantee a similar outcome.

公司名称: Integra LifeSciences Holdings Corporation
股票代号: IART
集体诉讼期: March 11, 2019 through May 22, 2023
法院: United States District Court for the District of New Jersey


自 2013 年以来,罗森律师事务所每年都是代表投资者成功提起证券集体诉讼的前四大律所之一。仅 2019 年,本律所就为投资者追回 4.38 亿美元资金。


机构股东服务公司按 2017 年证券集体诉讼索赔数量,罗森律师事务所列为第一名。


Scroll to Top